Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28476947 | 0.95 | HSD17B10 (0.50) | HSD17B10IMPDH2MAPK1CDK8MAPT | |
| SCHEMBL17014784 | 0.79 | MEN1 (0.70) | HSD17B10IMPDH2MAPK1MAPTALDH1A1 | |
| SCHEMBL31140513 | 0.78 | GPR84 (0.46) | CDK8MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL28196184 | 0.78 | MAPT (0.50) | MAPK1CDK8MAPTALDH1A1MEN1 | |
| SCHEMBL28775869 | 0.78 | IMPDH2 (0.55) | IMPDH2CDK8MAPTALDH1A1MEN1 | |
| SCHEMBL28855480 | 0.78 | MEN1 (0.52) | IMPDH2CDK8MAPTALDH1A1MEN1 | |
| SCHEMBL7584509 | 0.78 | CDK8 (0.41) | HSD17B10IMPDH2MAPK1CDK8MAPT | |
| SCHEMBL14023504 | 0.78 | MAPT (0.62) | HSD17B10MAPK1MAPTALDH1A1MEN1 | |
| SCHEMBL1202543 | 0.77 | IMPDH2 (0.63) | HSD17B10IMPDH2MAPK1MAPTALDH1A1 | |
| SCHEMBL31690450 | 0.76 | PIK3CD (0.53) | HSD17B10MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114014859-A | Triazole indolol compound and synthesis method thereof | 绍兴文理学院 | 2022-02-08 | — | — | CN | claimed |
| CN-111100056-B | Synthetic method for preparing 3-thiophenyl indole compound by oxygen oxidation without transition metal catalysis | 浙江工业大学 | 2021-07-06 | — | — | CN | claimed |
| CN-111100056-A | Synthetic method for preparing 3-thiophenyl indole compound by oxygen oxidation without transition metal catalysis | 浙江工业大学 | 2020-05-05 | — | — | CN | claimed |
| US-8802153-B2 | System for targeted delivery of therapeutic agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-08-12 | — | — | US | claimed |
| US-8709483-B2 | System for targeted delivery of therapeutic agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-04-29 | — | — | US | claimed |
| US-20140017327-A1 | System for Targeted Delivery of Therapeutic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-01-16 | — | — | US | claimed |
| US-20100266491-A1 | SYSTEM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-10-21 | — | — | US | claimed |
| EP-2007435-A2 | SYSTEM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | The Brigham and Women's Hospital, Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2008105773-A2 | SYSTEM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-09-04 | — | — | WO | claimed |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | CYTODIGM, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260000700-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2026-01-01 | — | — | US | disclosed |
| US-20260000771-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2026-01-01 | — | — | US | disclosed |
| WO-2025238236-A1 | POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL | TARGIMMUNE THERAPEUTICS AG (CH) | 2025-11-20 | — | — | WO | disclosed |
| EP-4615511-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TargImmune Therapeutics AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| CN-100351236-C | 1-heterocyclylalkyl-3-sulfonyl-indole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and their use | WYETH CORP (US) | 2007-11-28 | — | — | CN | disclosed |
| CN-1261412-C | Indole derivatives as COXII inhibitors | HOFFMANN LA ROCHE (CH) | 2006-06-28 | — | — | CN | disclosed |
| CN-1668590-A | 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2005-09-14 | — | — | CN | disclosed |
| CN-1656069-A | 1-(aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2005-08-17 | — | — | CN | disclosed |
| CN-1561334-A | Indole derivatives as COXII inhibitors | HOFFMANN LA ROCHE (CH) | 2005-01-05 | — | — | CN | disclosed |
| US-6225334-B1 | AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000771-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | PSMA1, PSMA3, PSMA2 | HSD17B10 4353/4885IMPDH2 3223/4885MAPK1 3114/4885 |
| US-20260000700-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | CTDSP1, POLM, MCTS1 | HSD17B10 4362/4885IMPDH2 4291/4885MAPK1 2179/4885 |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | SIGLEC7, SIGLEC9, CD2 | HSD17B10 4688/4885IMPDH2 3366/4885MAPK1 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.